{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:22:07Z","timestamp":1792898527689,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.vaccine.2021.03.043","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T03:11:21Z","timestamp":1616555481000},"page":"2965-2975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Chlamydia trachomatis: Cell biology, immunology and vaccination"],"prefix":"10.1016","volume":"39","author":[{"given":"Sam M.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2021.03.043_b0005","doi-asserted-by":"crossref","first-page":"548","DOI":"10.2471\/BLT.18.228486","article-title":"Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016","volume":"97","author":"Rowley","year":"2019","journal-title":"Bull World Health Organ"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_b0010","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1128\/iai.41.2.865-868.1983","article-title":"Immunotypes of Chlamydia trachomatis isolates in Seattle","volume":"41","author":"Kuo","year":"1983","journal-title":"Washington Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2021.03.043_b0015","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"The Lancet Global Health"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2008.02647.x","article-title":"Genital Chlamydia trachomatis infections","volume":"15","author":"B\u00e9b\u00e9ar","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_b0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0956462414531243","article-title":"Risk for HIV following a diagnosis of syphilis, gonorrhoea or chlamydia: 328,456 women in Florida, 2000\u20132011","volume":"26","author":"Peterman","year":"2014","journal-title":"Int J STD AIDS"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0030","first-page":"697","article-title":"Lymphogranuloma venereum among men who have sex with men. An epidemiological and clinical review. Expert Review of Anti-infective","volume":"12","author":"de Vrieze","year":"2014","journal-title":"Therapy"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_b0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciu220","article-title":"Azithromycin versus doxycycline for the treatment of genital chlamydia infection: a meta-analysis of randomized controlled trials","volume":"59","author":"Kong","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.043_b0040","series-title":"Report of the 21st meeting of the WHO alliance for the global elimination of trachoma by 2020, Geneva, Switzerland, 20\u201322 April 2017","author":"Organization","year":"2019"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0045","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/OLQ.0b013e318206c288","article-title":"The incidence and correlates of symptomatic and asymptomatic Chlamydia trachomatis and Neisseria gonorrhoeae infections in selected populations in five countries","volume":"38","author":"Detels","year":"2011","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2021.03.043_b0050","unstructured":"W.H.O. Global Health Sector Strategy on Sexually Transmitted Infections 2016-2021. Geneva, Switzerland; 2016."},{"key":"10.1016\/j.vaccine.2021.03.043_b0055","doi-asserted-by":"crossref","unstructured":"Mariotti SP, Pararajasegaram R, Resnikoff S. Trachoma: Looking Forward to Global Elimination of Trachoma by 2020 (GET 2020). The American Journal of Tropical Medicine and Hygiene Am J Trop Med Hyg. 2003;69(5_suppl_1):33-5.","DOI":"10.4269\/ajtmh.2003.69.5_suppl_1.0690033"},{"key":"10.1016\/j.vaccine.2021.03.043_b0060","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jprot.2014.05.009","article-title":"Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques","volume":"108","author":"Patton","year":"2014","journal-title":"J Proteomics"},{"issue":"12","key":"10.1016\/j.vaccine.2021.03.043_b0065","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/infdis\/jit094","article-title":"Spontaneous resolution of genital chlamydia trachomatis infection in women and protection from reinfection","volume":"207","author":"Geisler","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.043_b0070","doi-asserted-by":"crossref","unstructured":"Benoun JM, Labuda JC, McSorley SJ. Collateral damage: detrimental effect of antibiotics on the development of protective immune memory. mBio. 2016;7(6):e01520-16.","DOI":"10.1128\/mBio.01520-16"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0075","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1038\/s41598-020-67208-x","article-title":"Vaccination of koalas during antibiotic treatment for Chlamydia-induced cystitis induces an improved antibody response to Chlamydia pecorum","volume":"10","author":"Phillips","year":"2020","journal-title":"Sci Rep"},{"issue":"50","key":"10.1016\/j.vaccine.2021.03.043_b0080","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1016\/j.vaccine.2017.01.023","article-title":"Status of vaccine research and development of vaccines for Chlamydia trachomatis infection","volume":"37","author":"Poston","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.043_b0085","first-page":"157","article-title":"Etude experimentale du trachome","volume":"4","author":"Nicolle","year":"1913","journal-title":"Arch Instit Pasteur de Tunis"},{"issue":"14","key":"10.1016\/j.vaccine.2021.03.043_b0090","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.vaccine.2013.10.016","article-title":"Towards a safe and effective chlamydial vaccine: Lessons from the eye","volume":"32","author":"Mabey","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrmicro.2016.30","article-title":"Chlamydia cell biology and pathogenesis","volume":"14","author":"Elwell","year":"2016","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_b0100","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1128\/CMR.00105-13","article-title":"Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research","volume":"27","author":"Vasilevsky","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2021.03.043_b0105","doi-asserted-by":"crossref","unstructured":"Olivares-Zavaleta N, Whitmire WM, Kari L, Sturdevant GL, Caldwell HD. CD8+ T cells define an unexpected role in live-attenuated vaccine protective immunity against Chlamydia trachomatis infection in macaques. Journal of immunology (Baltimore, Md : 1950). 2014;192(10):4648-54.","DOI":"10.4049\/jimmunol.1400120"},{"issue":"66","key":"10.1016\/j.vaccine.2021.03.043_b0110","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1098\/rsif.2011.0131","article-title":"Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data","volume":"9","author":"Althaus","year":"2012","journal-title":"J R Soc Interface"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/jb.178.1.1-5.1996","article-title":"Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae?","volume":"178","author":"Hatch","year":"1996","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2021.03.043_b0120","doi-asserted-by":"crossref","first-page":"10114","DOI":"10.1038\/ncomms10114","article-title":"Structure of a bacterial type III secretion system in contact with a host membrane in situ","volume":"6","author":"Nans","year":"2015","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.vaccine.2021.03.043_b0125","doi-asserted-by":"crossref","first-page":"11143","DOI":"10.1073\/pnas.93.20.11143","article-title":"A recombinant Chlamydia trachomatis major outer membrane protein binds to heparan sulfate receptors on epithelial cells","volume":"93","author":"Su","year":"1996","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/CBI20090227","article-title":"CFTR is required for cellular entry and internalization of Chlamydia trachomatis","volume":"34","author":"Ajonuma","year":"2010","journal-title":"Cell Biol Int"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.043_b0135","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.micinf.2015.08.004","article-title":"Host-pathogen reorganisation during host cell entry by Chlamydia trachomatis","volume":"17","author":"Nans","year":"2015","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2021.03.043_b0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev.cellbio.18.012502.105845","article-title":"The chlamydial inclusion: escape from the endocytic pathway","volume":"18","author":"Fields","year":"2002","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"14","key":"10.1016\/j.vaccine.2021.03.043_b0145","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1073\/pnas.1331135100","article-title":"Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis","volume":"100","author":"Belland","year":"2003","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.043_b0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063426","article-title":"Role for Chlamydial Inclusion Membrane Proteins in Inclusion Membrane Structure and Biogenesis","volume":"8","author":"Mital","year":"2013","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_b0155","doi-asserted-by":"crossref","first-page":"e00203","DOI":"10.1128\/CVI.00203-17","article-title":"Chlamydia trachomatis: the persistent pathogen","volume":"24","author":"Witkin","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"9","key":"10.1016\/j.vaccine.2021.03.043_b0160","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1073\/pnas.90.9.3998","article-title":"Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro","volume":"90","author":"Beatty","year":"1993","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_b0165","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1128\/IAI.72.4.1843-1855.2004","article-title":"Chlamydial persistence: beyond the biphasic paradigm","volume":"72","author":"Hogan","year":"2004","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0170","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mib.2006.12.003","article-title":"Chlamydial interferon gamma immune evasion influences infection tropism","volume":"10","author":"McClarty","year":"2007","journal-title":"Curr Opin Microbiol"},{"issue":"3101","key":"10.1016\/j.vaccine.2021.03.043_b0175","article-title":"Chlamydia persistence: a survival strategy to evade antimicrobial effects in-vitro and in-vivo","volume":"9","author":"Panzetta","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2021.03.043_b0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fcimb.2014.00071","article-title":"Morphologic and molecular evaluation of Chlamydia trachomatis growth in human endocervix reveals distinct growth patterns","volume":"4","author":"Lewis","year":"2014","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.043_b0185","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/infdis\/jix155","article-title":"Demonstration of persistent infections and genome stability by whole-genome sequencing of repeat-positive, same-serovar chlamydia trachomatis collected from the female genital tract","volume":"215","author":"Suchland","year":"2017","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.043_b0190","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/j.1462-5822.2009.01364.x","article-title":"New insights into Chlamydia intracellular survival mechanisms","volume":"11","author":"Cocchiaro","year":"2009","journal-title":"Cell Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0195","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-017-02432-0","article-title":"Replication-dependent size reduction precedes differentiation in Chlamydia trachomatis","volume":"9","author":"Lee","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_b0200","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1128\/JB.185.10.3179-3189.2003","article-title":"Global stage-specific gene regulation during the developmental cycle of Chlamydia trachomatis","volume":"185","author":"Nicholson","year":"2003","journal-title":"J Bacteriol"},{"issue":"27","key":"10.1016\/j.vaccine.2021.03.043_b0205","doi-asserted-by":"crossref","first-page":"11430","DOI":"10.1073\/pnas.0703218104","article-title":"Mechanisms of host cell exit by the intracellular bacterium Chlamydia","volume":"104","author":"Hybiske","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2021.03.043_b0210","doi-asserted-by":"crossref","unstructured":"Sangiuliano B, P\u00e9rez NM, Moreira DF, Beliz\u00e1rio JE. Cell death-associated molecular-pattern molecules: inflammatory signaling and control. Mediators Inflamm. 2014;2014:821043-.","DOI":"10.1155\/2014\/821043"},{"issue":"9","key":"10.1016\/j.vaccine.2021.03.043_b0215","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/j.1462-5822.2007.00945.x","article-title":"Lysosome repair enables host cell survival and bacterial persistence following Chlamydia trachomatis infection","volume":"9","author":"Beatty","year":"2007","journal-title":"Cell Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_b0220","doi-asserted-by":"crossref","DOI":"10.1111\/cmi.12683","article-title":"Extrusions are phagocytosed and promote Chlamydia survival within macrophages","volume":"19","author":"Zuck","year":"2017","journal-title":"Cell Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.043_b0225","doi-asserted-by":"crossref","first-page":"e00046","DOI":"10.1128\/IAI.00046-17","article-title":"Chlamydia trachomatis cellular exit alters interactions with host dendritic cells","volume":"85","author":"Sherrid","year":"2017","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.03.043_b0230","doi-asserted-by":"crossref","unstructured":"Yang C, Briones M, Chiou J, Lei L, Patton MJ, Ma L, et al. Chlamydia trachomatis Lipopolysaccharide Evades the Canonical and Noncanonical Inflammatory Pathways To Subvert Innate Immunity. mBio. 2019;10(2):e00595-19.","DOI":"10.1128\/mBio.00595-19"},{"issue":"7489","key":"10.1016\/j.vaccine.2021.03.043_b0235","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature12892","article-title":"A new metabolic cell-wall labelling method reveals peptidoglycan in Chlamydia trachomatis","volume":"506","author":"Liechti","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.vaccine.2021.03.043_b0240","doi-asserted-by":"crossref","first-page":"414","DOI":"10.15698\/mic2019.09.691","article-title":"The multiple functions of the numerous Chlamydia trachomatis secreted proteins: the tip of the iceberg","volume":"6","author":"Bugalh\u00e3o","year":"2019","journal-title":"Microb Cell"},{"key":"10.1016\/j.vaccine.2021.03.043_b0245","first-page":"p.]","article-title":"Modeling of variables in cellular infection reveals CXCL10 levels are regulated by human genetic variation and the Chlamydia-encoded CPAF protease","volume":"10(1):[18269","author":"Schott","year":"2020","journal-title":"Scientific reports [Internet]"},{"key":"10.1016\/j.vaccine.2021.03.043_b0250","doi-asserted-by":"crossref","unstructured":"Patton MJ, McCorrister S, Grant C, Westmacott G, Fariss R, Hu P, et al. Chlamydial protease-like activity factor and type III secreted effectors cooperate in inhibition of p65 nuclear translocation. mBio. 2016;7(5):e01427-16.","DOI":"10.1128\/mBio.01427-16"},{"key":"10.1016\/j.vaccine.2021.03.043_b0255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2019.05.007","article-title":"Apoptosis inhibition by intracellular bacteria and its consequence on host immunity","volume":"60","author":"Behar","year":"2019","journal-title":"Curr Opin Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.043_b0260","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.celrep.2014.10.004","article-title":"Tumor suppressor p53 alters host cell metabolism to limit chlamydia trachomatis infection","volume":"9","author":"Siegl","year":"2014","journal-title":"Cell Reports"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.chom.2011.06.008","article-title":"The Chlamydia protease CPAF regulates host and bacterial proteins to maintain pathogen vacuole integrity and promote virulence","volume":"10","author":"Jorgensen","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0270","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/femsre\/fuw027","article-title":"Sensing the enemy, containing the threat: cell-autonomous immunity to Chlamydia trachomatis","volume":"40","author":"Finethy","year":"2016","journal-title":"FEMS Microbiol Rev"},{"issue":"33","key":"10.1016\/j.vaccine.2021.03.043_b0275","doi-asserted-by":"crossref","first-page":"31332","DOI":"10.1074\/jbc.M103217200","article-title":"Endocytosed HSP60s Use Toll-like Receptor 2 (TLR2) and TLR4 to Activate the Toll\/Interleukin-1 Receptor Signaling Pathway in Innate Immune Cells","volume":"276","author":"Vabulas","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0280","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/IAI.01062-12","article-title":"Toll-like receptor 2-dependent activity of native major outer membrane protein proteosomes of chlamydia trachomatis","volume":"81","author":"Massari","year":"2013","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.043_b0285","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1128\/IAI.01118-10","article-title":"Toll-like receptor 2 activation by chlamydia trachomatis is plasmid dependent, and plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by C. trachomatis but Not by C. muridarum","volume":"79","author":"O'Connell","year":"2011","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.043_b0290","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.4049\/jimmunol.171.11.6187","article-title":"Toll-like receptor-2, but not toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection","volume":"171","author":"Darville","year":"2003","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.043_b0295","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1074\/jbc.M510182200","article-title":"Localization of TLR2 and MyD88 to Chlamydia trachomatis inclusions. Evidence for signaling by intracellular TLR2 during infection with an obligate intracellular pathogen","volume":"281","author":"O'Connell","year":"2006","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.vaccine.2021.03.043_b0300","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.03.043_b0305","doi-asserted-by":"crossref","unstructured":"Barker JR, Koestler BJ, Carpenter VK, Burdette DL, Waters CM, Vance RE, et al. STING-dependent recognition of cyclic di-AMP mediates type I interferon responses during Chlamydia trachomatis infection. mBio. 2013;4(3).","DOI":"10.1128\/mBio.00018-13"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_b0310","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1128\/IAI.00629-08","article-title":"Type I interferon signaling exacerbates Chlamydia muridarum genital infection in a murine model","volume":"76","author":"Nagarajan","year":"2008","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_b0315","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/infdis\/jiz087","article-title":"Cervical cytokines associated with chlamydia trachomatis susceptibility and protection","volume":"220","author":"Poston","year":"2019","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.043_b0320","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/iai.57.11.3484-3490.1989","article-title":"Reversion of the antichlamydial effect of tumor necrosis factor by tryptophan and antibodies to beta interferon","volume":"57","author":"Shemer-Avni","year":"1989","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0325","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2021.03.043_b0330","doi-asserted-by":"crossref","unstructured":"Pontiroli F, Dussurget O, Zanoni I, Urbano M, Beretta O, Granucci F, et al. The timing of IFN\u03b2 production affects early innate responses to Listeria monocytogenes and determines the overall outcome of lethal infection. PLoS One. 2012;7(8):e43455-e.","DOI":"10.1371\/journal.pone.0043455"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.043_b0335","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/1521-4141(200203)32:3<742::AID-IMMU742>3.0.CO;2-9","article-title":"Uptake and processing of Chlamydia trachomatis by human dendritic cells","volume":"32","author":"Matyszak","year":"2002","journal-title":"Eur J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.03.043_b0340","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1128\/IAI.69.7.4667-4672.2001","article-title":"Expression of genes encoding th1 cell-activating cytokines and lymphoid homing chemokines by chlamydia-pulsed dendritic cells correlates with protective immunizing efficacy","volume":"69","author":"Shaw","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.03.043_b0345","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.imlet.2018.08.002","article-title":"Diversity in the T cell response to Chlamydia-sum are better than one","volume":"202","author":"Labuda","year":"2018","journal-title":"Immunol Lett"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0350","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.4049\/jimmunol.1002952","article-title":"Immunization with live and dead chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional th1 cells","volume":"186","author":"Yu","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.03.043_b0355","doi-asserted-by":"crossref","unstructured":"Arulanandam B, Li W, Murthy A, Chaganty B, Guentzel M, seshu j, et al. Immunization with dendritic cells pulsed ex vivo with recombinant chlamydial protease-like activity factor induces protective immunity against genital chlamydiamuridarum challenge. Frontiers in Immunology. 2011;2(73).","DOI":"10.3389\/fimmu.2011.00073"},{"issue":"8","key":"10.1016\/j.vaccine.2021.03.043_b0360","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1128\/IAI.01618-06","article-title":"Survival of chlamydia muridarum within dendritic cells","volume":"75","author":"Rey-Ladino","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.03.043_b0365","doi-asserted-by":"crossref","unstructured":"Faris R, Andersen SE, McCullough A, Gourronc F, Klingelhutz AJ, Weber MM. Chlamydia trachomatis serovars drive differential production of proinflammatory cytokines and chemokines depending on the type of cell infected. Frontiers in Cell Infect Microbiol 2019;9:399-.","DOI":"10.3389\/fcimb.2019.00399"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.043_b0370","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1128\/iai.48.3.847-849.1985","article-title":"Chronic chlamydial genital infection in congenitally athymic nude mice","volume":"48","author":"Rank","year":"1985","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.043_b0375","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2249.2004.02564.x","article-title":"Cytokine expression pattern in the genital tract of Chlamydia trachomatis positive infertile women - implication for T-cell responses","volume":"137","author":"Reddy","year":"2004","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2021.03.043_b0380","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1128\/iai.63.12.4661-4668.1995","article-title":"Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection","volume":"63","author":"Morrison","year":"1995","journal-title":"Infect Immun"},{"issue":"12","key":"10.1016\/j.vaccine.2021.03.043_b0385","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.1128\/IAI.68.12.6979-6987.2000","article-title":"Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells","volume":"68","author":"Morrison","year":"2000","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2021.03.043_b0390","doi-asserted-by":"crossref","unstructured":"Lijek RS, Helble JD, Olive AJ, Seiger KW, Starnbach MN. Pathology after Chlamydia trachomatis infection is driven by nonprotective immune cells that are distinct from protective populations. Proceedings of the National Academy of Sciences. 2018;115(9):2216","DOI":"10.1073\/pnas.1711356115"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_b0395","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1128\/iai.63.2.516-521.1995","article-title":"Role of CD8 T cells in primary Chlamydia infection","volume":"63","author":"Magee","year":"1995","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.043_b0400","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1084\/jem.20111266","article-title":"A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates","volume":"208","author":"Kari","year":"2011","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_b0405","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1128\/iai.59.10.3774-3777.1991","article-title":"Role of L3T4-bearing T-cell populations in experimental murine chlamydial salpingitis","volume":"59","author":"Landers","year":"1991","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.043_b0410","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/jir.1989.9.329","article-title":"Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages","volume":"9","author":"Carlin","year":"1989","journal-title":"J Interferon Res"},{"issue":"3","key":"10.1016\/j.vaccine.2021.03.043_b0415","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4161\/viru.20328","article-title":"The potential of nitric oxide releasing therapies as antimicrobial agents","volume":"3","author":"Schairer","year":"2012","journal-title":"Virulence"},{"issue":"8","key":"10.1016\/j.vaccine.2021.03.043_b0420","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1128\/IAI.69.8.5131-5137.2001","article-title":"Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome","volume":"69","author":"Ramsey","year":"2001","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0425","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1128\/IAI.74.1.225-238.2006","article-title":"Comparison of gamma interferon-mediated antichlamydial defense mechanisms in human and mouse cells","volume":"74","author":"Roshick","year":"2006","journal-title":"Infect Immun"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0430","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.4049\/jimmunol.1400377","article-title":"Chlamydia trachomatis inhibits inducible NO synthase in human mesenchymal stem cells by stimulating polyamine synthesis","volume":"193","author":"Abu-Lubad","year":"2014","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_b0435","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.4049\/jimmunol.1102764","article-title":"Plac8-dependent and inducible NO synthase-dependent mechanisms clear chlamydia muridarum infections from the genital tract","volume":"188","author":"Johnson","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2021.03.043_b0440","doi-asserted-by":"crossref","unstructured":"Ficarra M, Ibana JSA, Poretta C, Ma L, Myers L, Taylor SN, et al. A distinct cellular profile is seen in the human endocervix during Chlamydia trachomatis infection. Am J Reproductive Immunology (New York, NY : 1989). 2008;60(5):415-25.","DOI":"10.1111\/j.1600-0897.2008.00639.x"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0445","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/infdis\/162.6.1385","article-title":"Interferon-\u03b3 in endocervical secretions of women infected with chlamydia trachomatis","volume":"162","author":"Arno","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.043_b0450","doi-asserted-by":"crossref","unstructured":"Lee DAE, Zhong W, Dong L, Russell AR, O\u2019Connell C, Wiesenfeld H, et al. Increased levels of Th1-inducing cytokines are detected in cervical secretions of women with Chlamydia trachomatis infection limited to their cervix. J Immunol 2018;200(1 Supplement):172.15-.15","DOI":"10.4049\/jimmunol.200.Supp.172.15"},{"issue":"8","key":"10.1016\/j.vaccine.2021.03.043_b0455","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/sextrans-2014-051601","article-title":"Defining genital tract cytokine signatures of sexually transmitted infections and bacterial vaginosis in women at high risk of HIV infection: A cross-sectional study","volume":"90","author":"Masson","year":"2014","journal-title":"Sexually Transmitted Infections"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_b0460","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/432070","article-title":"Immunoepidemiologic profile of chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon-\u03b3","volume":"192","author":"Cohen","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.043_b0465","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2018.01981","article-title":"An adaptive chlamydia trachomatis-specific IFN-gamma-producing CD4(+) T cell response is associated with protection against chlamydia reinfection in women","volume":"9","author":"Bakshi","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_b0470","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1128\/IAI.69.4.2643-2649.2001","article-title":"Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells","volume":"69","author":"Morrison","year":"2001","journal-title":"Infect Immun"},{"issue":"17","key":"10.1016\/j.vaccine.2021.03.043_b0475","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1016\/j.vaccine.2009.12.020","article-title":"Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays","volume":"28","author":"Molina","year":"2010","journal-title":"Vaccine"},{"issue":"24","key":"10.1016\/j.vaccine.2021.03.043_b0480","doi-asserted-by":"crossref","first-page":"9969","DOI":"10.1073\/pnas.1101756108","article-title":"Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines","volume":"108","author":"Finco","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0485","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1086\/528378","article-title":"Antigenic profiling of a chlamydia trachomatis gene-expression library","volume":"197","author":"Follmann","year":"2008","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.043_b0490","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4049\/jimmunol.113.5.1607","article-title":"The role of immunoglobulin in the neutralization of trachoma infectivity","volume":"113","author":"Barenfanger","year":"1974","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0495","doi-asserted-by":"crossref","first-page":"20181","DOI":"10.3402\/jev.v2i0.20181","article-title":"Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro","volume":"2","author":"Bartolini","year":"2013","journal-title":"J Extracellular Vesicles"},{"key":"10.1016\/j.vaccine.2021.03.043_b0500","article-title":"Protective effect of vaccine promoted neutralizing antibodies against the intracellular pathogen chlamydia trachomatis","author":"Olsen","year":"201781652","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_b0505","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2958.2000.02167.x","article-title":"Characterization and functional analysis of PorB, a Chlamydia porin and neutralizing target","volume":"38","author":"Kubo","year":"2000","journal-title":"Mol Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_b0510","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1073\/pnas.0508983103","article-title":"Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen","volume":"103","author":"Crane","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_b0515","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003707","article-title":"B cells enhance antigen-specific CD4 T cell priming and prevent bacteria dissemination following chlamydia muridarum genital tract infection","volume":"9","author":"Li","year":"2013","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.043_b0520","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/eji.201948391","article-title":"Antibody, but not B-cell\u2013dependent antigen presentation, plays an essential role in preventing Chlamydia systemic dissemination in mice","volume":"50","author":"Malaviarachchi","year":"2020","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_b0525","doi-asserted-by":"crossref","first-page":"e00614","DOI":"10.1128\/IAI.00614-17","article-title":"B cell presentation of chlamydia antigen selects out protective CD4\u03b313 T cells: implications for genital tract tissue-resident memory lymphocyte clusters","volume":"86","author":"Johnson","year":"2018","journal-title":"Infect Immun"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.043_bib606","first-page":"471","article-title":"The Immunology of the Trachoma Agent With a Preliminary Report on Field Trials of Vaccine","volume":"2","author":"Bell","year":"1963","journal-title":"Invest Ophth Vis Sci"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_bib607","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4269\/ajtmh.1963.12.909","article-title":"Studies on Trachoma: Investigations in Portugal on Formalin-Killed Trachoma Vaccines with Special Reference to Serologic Response","volume":"12","author":"Sampaio","year":"1963","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_bib608","first-page":"233","article-title":"The present status of trachoma vaccination studies","volume":"34","author":"Collier","year":"1966","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2021.03.043_bib609","doi-asserted-by":"crossref","unstructured":"Dhir SP, Agarwal LP, Detels R, Wang S-p, Thomas Grayston J. Field Trial of Two Bivalent Trachoma Vaccines in Children of Punjab Indian Villages. Am J Ophthalmol. 1967;63(5, Part 2):1639-44.","DOI":"10.1016\/0002-9394(67)94157-8"},{"key":"10.1016\/j.vaccine.2021.03.043_bib610","doi-asserted-by":"crossref","unstructured":"Woolridge RL, Grayston JT, Chang IH, Yang CY, Cheng KH. Long-Term Follow-Up of the Initial (1959\u20131960) Trachoma Vaccine Field Trial on Taiwan. Am J Ophthalmol. 1967;63(5, Part 2):1650-3.","DOI":"10.1016\/0002-9394(67)94159-1"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_bib611","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1017\/S0022172400042157","article-title":"Trachoma vaccine field trials in The Gambia","volume":"67","author":"Sowa","year":"1969","journal-title":"Epidemiol Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_bib612","first-page":"1722","article-title":"Attempted oral immunization with chlamydial lipopolysaccharide subunit vaccine","volume":"28","author":"Taylor","year":"1987","journal-title":"Invest Ophth Vis Sci"},{"issue":"12","key":"10.1016\/j.vaccine.2021.03.043_bib613","first-page":"1847","article-title":"Oral immunization with chlamydial major outer membrane protein (MOMP)","volume":"29","author":"Taylor","year":"1988","journal-title":"Invest Ophth Vis Sci"},{"issue":"8","key":"10.1016\/j.vaccine.2021.03.043_bib614","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1128\/iai.60.8.3428-3432.1992","article-title":"Characterization of the humoral response induced by a peptide corresponding to variable domain IV of the major outer membrane protein of Chlamydia trachomatis serovar E","volume":"60","author":"Cheng","year":"1992","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_bib615","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1128\/iai.61.10.4406-4414.1993","article-title":"A poliovirus hybrid expressing a neutralization epitope from the major outer membrane protein of Chlamydia trachomatis is highly immunogenic","volume":"61","author":"Murdin","year":"1993","journal-title":"Infect Immun"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.043_bib616","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/0264-410X(93)90080-H","article-title":"Immunogenicity of a synthetic oligopeptide corresponding to antigenically common T-helper and B-cell neutralizing epitopes of the major outer membrane protein of Chlamydia trachomatis","volume":"11","author":"Su","year":"1993","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_bib617","first-page":"8","article-title":"A peptide of Chlamydia trachomatis shown to be a primary T-cell epitope in vitro induces cell-mediated immunity in vivo","volume":"85","author":"Knight","year":"1995","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_bib618","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1086\/516545","article-title":"DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection","volume":"176","author":"Zhang","year":"1997","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_bib619","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1128\/IAI.68.6.3074-3078.2000","article-title":"Priming with Chlamydia trachomatis Major Outer Membrane Protein (MOMP) DNA followed by MOMP ISCOM Boosting Enhances Protection and Is Associated with Increased Immunoglobulin A and Th1 Cellular Immune Responses","volume":"68","author":"Dong-Ji","year":"2000","journal-title":"Infect Immun"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2021.03.043_bib620","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0264-410X(02)00631-X","article-title":"DNA immunization with pgp3 gene of Chlamydia trachomatis inhibits the spread of chlamydial infection from the lower to the upper genital tract in C3H\/HeN mice","volume":"21","author":"Donati","year":"2003","journal-title":"Vaccine"},{"issue":"15","key":"10.1016\/j.vaccine.2021.03.043_bib621","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0264-410X(02)00677-1","article-title":"Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis","volume":"21","author":"Eko","year":"2003","journal-title":"Vaccine"},{"issue":"31\u201332","key":"10.1016\/j.vaccine.2021.03.043_bib622","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1016\/j.vaccine.2004.04.035","article-title":"Immune response to the Chlamydia trachomatis outer membrane protein PorB","volume":"22","author":"Kawa","year":"2004","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2021.03.043_bib623","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.1128\/IAI.01119-06","article-title":"Chlamydial protease-like activity factor induces protective immunity against genital chlamydial infection in transgenic mice that express the human HLA-DR4 allele","volume":"74","author":"Murthy","year":"2006","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_bib624","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1365-2567.2007.02608.x","article-title":"Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines","volume":"122","author":"He","year":"2007","journal-title":"Immunology"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_bib625","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.vaccine.2007.12.048","article-title":"In silico identification and in vivo analysis of a novel T-cell antigen from Chlamydia, NrdB","volume":"26","author":"Barker","year":"2008","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2021.03.043_bib626","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s11427-008-0130-9","article-title":"Immunization with chlamydial plasmid protein pORF5 DNA vaccine induces protective immunity against genital chlamydial infection in mice","volume":"51","author":"Li","year":"2008","journal-title":"Sci China C Life Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2021.03.043_bib627","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1574-695X.2008.00527.x","article-title":"Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis","volume":"55","author":"Coler","year":"2009","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"21","key":"10.1016\/j.vaccine.2021.03.043_bib628","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1016\/j.vaccine.2011.03.027","article-title":"Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate","volume":"29","author":"Eko","year":"2011","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2021.03.043_bib629","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1016\/j.vaccine.2012.01.017","article-title":"High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge","volume":"30","author":"Picard","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2021.03.043_bib630","first-page":"2085","article-title":"Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine","volume":"8","author":"Fairley","year":"2013","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"10.1016\/j.vaccine.2021.03.043_bib631","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1007\/s00253-014-5517-x","article-title":"Hepatitis B virus surface antigen as delivery vector can enhance Chlamydia trachomatis MOMP multi-epitope immune response in mice","volume":"98","author":"Zhu","year":"2014","journal-title":"Appl Microbiol Biotechnol"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_bib632","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141209","article-title":"Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies","volume":"10","author":"Badamchi-Zadeh","year":"2015","journal-title":"PloS one"},{"issue":"6","key":"10.1016\/j.vaccine.2021.03.043_bib633","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/infdis\/jiv137","article-title":"Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein","volume":"212","author":"Olsen","year":"2015","journal-title":"J Infect Dis"},{"issue":"34","key":"10.1016\/j.vaccine.2021.03.043_bib634","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1016\/j.vaccine.2016.06.046","article-title":"Immunization with chlamydial type III secretion antigens reduces vaginal shedding and prevents fallopian tube pathology following live C. muridarum challenge","volume":"34","author":"Bulir","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.043_bib635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176401","article-title":"Lactobacillus plantarum producing a Chlamydia trachomatis antigen induces a specific IgA response after mucosal booster immunization","volume":"12","author":"Kuczkowska","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_bib636","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/vaccines6010002","article-title":"Structural and Immunological Characterization of Novel Recombinant MOMP-Based Chlamydial Antigens","volume":"6","author":"Madico","year":"2018","journal-title":"Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2021.03.043_bib637","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1473-3099(19)30279-8","article-title":"Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial","volume":"19","author":"Abraham","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2021.03.043_b0600","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jconrel.2019.04.043","article-title":"Effects of cationic adjuvant formulation particle type, fluidity and immunomodulators on delivery and immunogenicity of saRNA","volume":"304","author":"Blakney","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2021.03.043_b0535","doi-asserted-by":"crossref","unstructured":"Wang S-p, Thomas Grayston J, Russell Alexander E. Trachoma vaccine studies in monkeys. Am J Ophthalmol. 1967;63(5, Part 2):1615-30.","DOI":"10.1016\/0002-9394(67)94155-4"},{"issue":"8","key":"10.1016\/j.vaccine.2021.03.043_b0545","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1128\/iai.65.8.3361-3369.1997","article-title":"Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge","volume":"65","author":"Pal","year":"1997","journal-title":"Infect Immun"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_b0550","doi-asserted-by":"crossref","first-page":"e00543","DOI":"10.1128\/CVI.00543-16","article-title":"Update on Chlamydia trachomatis vaccinology","volume":"24","author":"de la Maza","year":"2017","journal-title":"Clin Vaccine Immunol"},{"issue":"70","key":"10.1016\/j.vaccine.2021.03.043_b0560","article-title":"Seventy years of chlamydia vaccine research \u2013 limitations of the past and directions for the future","volume":"10","author":"Phillips","year":"2019","journal-title":"Front Microbiol"},{"issue":"41","key":"10.1016\/j.vaccine.2021.03.043_b0565","doi-asserted-by":"crossref","first-page":"43281","DOI":"10.18632\/oncotarget.6533","article-title":"Hepatitis B virus core antigen as a carrier for Chlamydia trachomatis MOMP multi-epitope peptide enhances protection against genital chlamydial infection","volume":"6","author":"Jiang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.vaccine.2021.03.043_b0570","doi-asserted-by":"crossref","unstructured":"Tifrea DF, Pal S, Fairman J, Massari P, de la Maza LM. Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold. npj Vaccines. 2020;5(1):37.","DOI":"10.1038\/s41541-020-0182-9"},{"issue":"5","key":"10.1016\/j.vaccine.2021.03.043_b0575","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0264-410X(98)00219-9","article-title":"Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against a genital challenge","volume":"17","author":"Pal","year":"1999","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.vaccine.2021.03.043_b0580","doi-asserted-by":"crossref","first-page":"33241","DOI":"10.18632\/oncotarget.16601","article-title":"DNA plasmid vaccine carrying Chlamydia trachomatis (Ct) major outer membrane and human papillomavirus 16L2 proteins for anti-Ct infection","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13721-016-0142-5","article-title":"Designing and modeling of complex DNA vaccine based on MOMP of Chlamydia trachomatis: an in silico approach","volume":"6","author":"Farhadi","year":"2016","journal-title":"Network Modeling Analysis in Health Informatics and Bioinformatics"},{"key":"10.1016\/j.vaccine.2021.03.043_b0590","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.3389\/fimmu.2018.02369","volume":"9","author":"Verma","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2021.03.043_b0595","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"issue":"1","key":"10.1016\/j.vaccine.2021.03.043_b0605","doi-asserted-by":"crossref","first-page":"1800376","DOI":"10.1002\/biot.201800376","article-title":"Emerging technologies for low-cost, rapid vaccine manufacture","volume":"14","author":"Kis","year":"2019","journal-title":"Biotechnol J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21003261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21003261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:57:33Z","timestamp":1759402653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21003261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":150,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0264410X21003261"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chlamydia trachomatis: Cell biology, immunology and vaccination","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}